Gastrointestinal stromal tumors, version 2.2014

Margaret von Mehren; R Lor Randall; Robert S Benjamin; Sarah Boles; Marilyn M Bui; Ephraim S Casper; Ernest U Conrad 3rd; Thomas F DeLaney; Kristen N Ganjoo; Suzanne George; Ricardo J Gonzalez; Martin J Heslin; John M Kane 3rd; Joel Mayerson; Sean V McGarry; Christian Meyer; Richard J O'Donnell; Alberto S Pappo; I Benjamin Paz; John D Pfeifer; Richard F Riedel; Scott Schuetze; Karen D Schupak; Herbert S Schwartz; Brian A Van Tine; Jeffrey D Wayne; Mary Anne Bergman; Hema Sundar

doi:10.6004/jnccn.2014.0080

Gastrointestinal stromal tumors, version 2.2014

J Natl Compr Canc Netw. 2014 Jun;12(6):853-62. doi: 10.6004/jnccn.2014.0080.

Authors

Margaret von Mehren¹, R Lor Randall¹, Robert S Benjamin¹, Sarah Boles¹, Marilyn M Bui¹, Ephraim S Casper¹, Ernest U Conrad 3rd¹, Thomas F DeLaney¹, Kristen N Ganjoo¹, Suzanne George¹, Ricardo J Gonzalez¹, Martin J Heslin¹, John M Kane 3rd¹, Joel Mayerson¹, Sean V McGarry¹, Christian Meyer¹, Richard J O'Donnell¹, Alberto S Pappo¹, I Benjamin Paz¹, John D Pfeifer¹, Richard F Riedel¹, Scott Schuetze¹, Karen D Schupak¹, Herbert S Schwartz¹, Brian A Van Tine¹, Jeffrey D Wayne¹, Mary Anne Bergman¹, Hema Sundar¹

Affiliation

¹ From Fox Chase Cancer Center; Huntsman Cancer Institute at the University of Utah; The University of Texas MD Anderson Cancer Center; UC San Diego Moores Cancer Center; Moffitt Cancer Center; Memorial Sloan-Kettering Cancer Center; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; Massachusetts General Hospital Cancer Center; Stanford Cancer Institute; Dana-Farber/Brigham and Women's Cancer Center; University of Alabama at Birmingham Comprehensive Cancer Center; Roswell Park Cancer Institute; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Fred & Pamela Buffett Cancer Center at The Nebraska Medical Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; UCSF Helen Diller Family Comprehensive Cancer Center; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; City of Hope Comprehensive Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; Duke Cancer Institute; University of Michigan Comprehensive Cancer Center; Vanderbilt-Ingram Cancer Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; and National Comprehensive Cancer Network.

PMID: 24925196
DOI: 10.6004/jnccn.2014.0080

Abstract

Gastrointestinal stromal tumors (GIST) are the most common soft tissue sarcoma of the gastrointestinal tract, resulting most commonly from KIT or platelet-derived growth factor receptor α (PDGFRα)-activating mutations. These NCCN Guideline Insights highlight the important updates to the NCCN Guidelines for Soft Tissue Sarcoma specific to the management of patients with GIST experiencing disease progression while on imatinib and/or sunitinib.

Publication types

Guideline
Research Support, Non-U.S. Gov't

MeSH terms

Benzamides / therapeutic use
Gastrointestinal Stromal Tumors / drug therapy*
Gastrointestinal Stromal Tumors / genetics*
Gastrointestinal Stromal Tumors / pathology
Humans
Imatinib Mesylate
Indoles / therapeutic use
Mutation
Piperazines / therapeutic use
Proto-Oncogene Proteins c-kit / genetics*
Pyrimidines / therapeutic use
Pyrroles / therapeutic use
Receptor, Platelet-Derived Growth Factor alpha / genetics*
Sunitinib

Substances

Benzamides
Indoles
Piperazines
Pyrimidines
Pyrroles
Imatinib Mesylate
Proto-Oncogene Proteins c-kit
Receptor, Platelet-Derived Growth Factor alpha
Sunitinib